Donner du sang pourrait faire bien plus que venir en aide aux autres — cela pourrait aussi améliorer la santé de vos propres cellules sanguines. Une étude récente suggère que les dons de sang fréquents pourraient favoriser la croissance de mutations bénéfiques dans les cellules sanguines, réduisant potentiellement le risque de maladies liées au sang.
AstraZeneca prend de l’avance avec son inhalateur Breztri Aerosphere, visant à élargir son utilisation au-delà de la maladie pulmonaire obstructive chronique (MPOC) pour traiter également l’asthme. Cette démarche pourrait rapprocher l’entreprise de son objectif de ventes annuelles de 3 à 5 milliards de dollars. Breztri est un inhalateur « 3-en-1 » qui combine trois médicaments pour faciliter
Une étude internationale récente a révélé qu’une seule dose d’un nouveau vaccin contre le virus respiratoire syncytial (VRS), appelé RSVPreF3 OA, peut protéger les adultes âgés de 60 ans et plus contre les infections pulmonaires graves causées par le VRS pendant jusqu’à trois saisons consécutives. L’étude a porté sur plus de 24 000 adultes âgés répartis
La Food and Drug Administration (FDA) des États-Unis a approuvé Nucala (mépolizumab) comme traitement d’appoint pour les adultes atteints de maladie pulmonaire obstructive chronique (MPOC) qui continuent de présenter des exacerbations malgré une triple thérapie inhalée. Nucala est le premier médicament biologique spécifiquement approuvé pour les patients MPOC présentant un « phénotype éosinophilique » — un groupe
A recent study by Uppsala University and Chalmers University of Technology has found that coffee from many workplace coffee machines contains high levels of cholesterol-raising compounds. The research, published in Nutrition, Metabolism & Cardiovascular Diseases, highlights the difference between coffee brewed in these machines and coffee made using regular paper filter drip coffee makers.
Novo Nordisk is exploring a higher-dose version of semaglutide to enhance weight loss treatments. In a recent phase 3b clinical trial called STEP UP, a 7.2-mg weekly dose of semaglutide helped participants lose an average of 20.7% of their body weight over 72 weeks. This significantly outperformed the 2.4-mg dose marketed as Wegovy, which led
Arrowhead Pharmaceuticals announced positive results from its Phase 3 PALISADE study on plozasiran, a new drug for treating familial chylomicronemia syndrome (FCS). FCS is a rare genetic condition that causes extremely high triglyceride levels, leading to serious health issues like acute pancreatitis. Currently, there are no approved treatments for FCS in the United States or
Merck & Co.’s new vaccine, CAPVAXIVE (V116), has been approved by the FDA for preventing invasive diseases and pneumonia in adults 18 and older caused by specific strains of the bacteria Streptococcus pneumoniae. This vaccine is particularly aimed at protecting adults over 50 from around 84% of invasive pneumococcal diseases. In several studies, CAPVAXIVE showed
Today the Team at JoinAStudy.ca would like to acknowledge the dedicated work of one of our Investigators, Dr. Sabeen Anwar. Dr. Anwar and her team have played a key part in gathering new data to advance the knowledge of patient care for the condition of Psoriatic Arthritis. The APPRAISE study, a prospective observational investigation conducted
Merck & Co. has presented data from a phase 3 trial showcasing the potential of its pneumococcal vaccine candidate, V116, to rival Pfizer’s current market dominance in vaccines of this nature. In the United States, Prevnar 20 (Pfizer’s vaccine) currently commands a dominant 95% share. However, Merck contends that V116 offers broader protection, making it
